Bronson Crouch is the Chief Executive Officer of Instil Bio, a biotechnology company focused on innovative cancer treatments. He has a solid academic background with an MBA from a well-regarded institution, which shows he knows how to manage and lead....

Bronson Crouch is the Chief Executive Officer of Instil Bio, a biotechnology company focused on innovative cancer treatments. He has a solid academic background with an MBA from a well-regarded institution, which shows he knows how to manage and lead. Born in 1978, Bronson has been with Instil Bio since its early days, having played a role in pivotal financing rounds that helped shape the company's future. His leadership has led to significant salary adjustments, reflecting the company’s growth and challenges in achieving corporate goals. Interestingly, Bronson holds a substantial amount of stock in the company, suggesting a strong personal investment in its success. In 2023, he received a total compensation of over $1.1 million, largely attributed to incentives aimed at keeping key talent in the company. His tenure has seen fluctuations in his personal financial portfolio, with notable drops in stock value amidst market challenges. Bronson's strategy focuses on attracting top talent and aligning executive pay with company performance, which is crucial in the competitive biotech field.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

I

Bronson Crouch

CEO of Instil Bio

Field of Expertise

Finance & Banking - Venture Capital

Sector of Economy

Healthcare

CEO of Instil Bio for

6 years 7 months (Nov 2018 - Present)

Previous Experience

Founding Partner of Curative Ventures Management LLC since January 2014

Rivals

Competitors/colleagues of Bronson Crouch

Holdings

See how much did Bronson Crouch make over time.

As the CEO of Instil Bio, Bronson Crouch's financial holdings have experienced notable changes over recent years. At the peak of 2021, his stakes were valued at about $1.03 billion but saw significant drops throughout 2022, ending the year at...

As the CEO of Instil Bio, Bronson Crouch's financial holdings have experienced notable changes over recent years. At the peak of 2021, his stakes were valued at about $1.03 billion but saw significant drops throughout 2022, ending the year at around $460.67 million. By mid-2023, his holdings continue to fluctuate, dropping to around $25 million. This pattern reflects the volatility of the biotechnology market, but it also underscores Crouch's significant investment in his company's future. Despite these ups and downs, his substantial share ownership—33.5% of the company—indicates a strong commitment to driving Instil Bio forward. It’s essential to note that his wealth is primarily tied to the company’s stock, making its performance critical to his financial wellbeing.

Mar 18, 2025

T

shares

TIL @ $20.99

Insider Trading

See recent insider trades of Bronson Crouch.

TIL

$9.00M

TIL at $20.00/share

Mar 23, 2021

Purchase

Compensation History

See how much did Bronson Crouch make over time.

In 2023, Bronson Crouch's total compensation at Instil Bio was $1,133,189. This included a salary of $684,653, a discretionary bonus of $423,833, and additional benefits worth $31,703. The bonus was designed to retain executives in line with corporate objectives. Interestingly, there were no stock options or grants vested in 2023, which highlights the challenges within the company and the hectic nature of the biotechnology industry. In 2022, Crouch's total compensation was significantly higher, at nearly $4.9 million, indicating variable performance metrics tied to company growth. His 2021 compensation stood at about $1 million, emphasizing the reliance on performance-based incentives to drive success.

Year

2023

Total Compensation

$1.14M

Salary

$684.65K

Board Justification

The compensation philosophy is designed to attract and retain top talent while aligning executive compensation with company performance and shareholder interests.

Bonus

$423.83K

Board Justification

Represents discretionary retention bonus payments, which are subject to repayment to the Company in full within 30 days of termination in the event the named executive officer resigns without good reason or is terminated for cause at any time on or prior to February 22, 2024.

Other

$31.70K

Board Justification

Includes $12,095 in employer contributions to a 401(k) plan and $17,072 in employer contributions to health insurance coverage.

Restricted Stock

$0.00(0 common stock)

Board Justification

No stock was reported as vested in 2023.

Performance Metrics

The performance metrics for the CEO's compensation in 2023 were based on the achievement of corporate goals.